Calcium phosphate microcrystallopathy as a paradigm of chronic kidney disease progression

被引:5
|
作者
Kuro-o, Makoto [1 ,2 ]
机构
[1] Jichi Med Univ, Ctr Mol Med, Div Antiaging Med, Shimotsuke, Tochigi, Japan
[2] Jichi Med Univ, Ctr Mol Med, Div Antiaging Med, 3311 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
来源
基金
日本学术振兴会;
关键词
calciprotein particles; inflammation; renal tubular damage; vascular calcification; CONTAINING CALCIPROTEIN PARTICLES; SMOOTH-MUSCLE-CELLS; CALCIFICATION; PROPENSITY;
D O I
10.1097/MNH.0000000000000890
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of reviewCalciprotein particles (CPP) are colloidal mineral-protein complexes mainly composed of solid-phase calcium phosphate and serum protein fetuin-A. CPP appear in the blood and renal tubular fluid after phosphate intake, playing critical roles in (patho)physiology of mineral metabolism and chronic kidney disease (CKD). This review aims at providing an update of current knowledge on CPP.Recent findingsCPP formation is regarded as a defense mechanism against unwanted growth of calcium phosphate crystals in the blood and urine. CPP are polydisperse colloids and classified based on the density and crystallinity of calcium phosphate. Low-density CPP containing amorphous (noncrystalline) calcium phosphate function as an inducer of FGF23 expression in osteoblasts and a carrier of calcium phosphate to the bone. However, once transformed to high-density CPP containing crystalline calcium phosphate, CPP become cytotoxic and inflammogenic, inducing cell death in renal tubular cells, calcification in vascular smooth muscle cells, and innate immune responses in macrophages.CPP potentially behave like a pathogen that causes renal tubular damage, chronic inflammation, and vascular calcification. CPP have emerged as a promising therapeutic target for CKD and cardiovascular complications.
引用
收藏
页码:344 / 351
页数:8
相关论文
共 50 条
  • [21] Disease Progression in Children with Chronic Kidney Disease
    Warady, Bradley
    Schwartz, George
    Wong, Craig
    Mitsnefes, Mark
    Kaskel, Frederick
    Greenbaum, Larry
    Mak, Robert
    Flynn, Joseph
    Moxey-Mims, Marva
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1493 - 1494
  • [22] Phosphate management in chronic kidney disease
    Bhan, Ishir
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (02): : 174 - 179
  • [23] Mechanisms of progression of chronic kidney disease
    Fogo, Agnes B.
    PEDIATRIC NEPHROLOGY, 2007, 22 (12) : 2011 - 2022
  • [24] Mechanisms of progression of chronic kidney disease
    Agnes B. Fogo
    Pediatric Nephrology, 2007, 22 : 2011 - 2022
  • [25] Targeting the progression of chronic kidney disease
    Marta Ruiz-Ortega
    Sandra Rayego-Mateos
    Santiago Lamas
    Alberto Ortiz
    Raul R. Rodrigues-Diez
    Nature Reviews Nephrology, 2020, 16 : 269 - 288
  • [26] Gender and the Progression of Chronic Kidney Disease
    Neugarten, Joel
    MAYO CLINIC PROCEEDINGS, 2020, 95 (12) : 2582 - 2584
  • [27] Retarding progression of chronic kidney disease
    Saritas, Turgay
    Floege, Juergen
    INNERE MEDIZIN, 2023, 64 (03): : 240 - 246
  • [28] PROGRESSION AND PREVENTION OF CHRONIC KIDNEY DISEASE
    Ojo, Afolabi Michael
    Oluwasegun, Sulaimon Akeem
    NEPHROLOGY, 2005, 10 : A135 - A135
  • [29] Acidosis and progression of chronic kidney disease
    Yaqoob, Muhammad M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (05): : 489 - 492
  • [30] Atheroma Progression in Chronic Kidney Disease
    Rigatto, Claudio
    Levin, Adeera
    House, Andrew A.
    Barrett, Brendan
    Carlisle, Euan
    Fine, Adrian
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02): : 291 - 298